Home cell
 

Keywords :   


Tag: cell

Updated KEYTRUDA (pembrolizumab) Data in Small Cell Lung Cancer and Mesothelioma Presented at 17th World Conference on Lung Cancer

2016-12-06 14:20:00| Merck.com - Product News

Dateline City: KENILWORTH, N.J. Findings in Small Cell Lung Cancer and Malignant Pleural Mesothelioma Show Overall Response Rates of 33.3 Percent and 20.0 Percent, Respectively, in KEYNOTE-028 Long-Term Data Demonstrate Durable Responses in Difficult-to-Treat Cancers KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that updated findings from the phase 1b KEYNOTE-028 study investigating the use of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in previously treated patients with advanced small cell lung cancer (SCLC) and malignant pleural mesothelioma, showed clinical activity and durable responses in some patients. Language: English Contact: Media:Pamela Eisele, 267-305-3558orCourtney Ronaldo, 908-236-1108orInvestorsTeri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more

Tags: on world data small

 

Nikola Motor unveils prototype Class 8 fuel cell range-extended electric truck, plans for H2 fueling network

2016-12-06 11:55:29| Green Car Congress

Tags: class network plans cell

 
 

First Honda Clarity Fuel Cell vehicles arrive in Europe as part of HyFIVE demo

2016-12-04 12:55:30| Green Car Congress

Tags: of part europe cell

 

NREL report finds hydrogen fuel cell bus fuel economy up to 1.4x that of diesel, 1.9x CNG

2016-12-01 11:55:27| Green Car Congress

Tags: report cell economy bus

 

Wrights Group showcases hydrogen fuel cell bus driveline in London; production-ready in 2017

2016-11-30 16:55:27| Green Car Congress

Tags: in group cell london

 

Sites : [87] [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] next »